Kineta closes patient enrollment in Phase Ib trial of ShK-186 to treat psoriasis

US-based biotechnology company Kineta has completed patient enrolment in its Phase Ib proof-of-concept clinical trial of its new, immune-sparing therapeutic, ShK-186, to treat psoriasis.

Category One, Showcase, status, Uncategorized, What's Hot